Introduction
============

Ovarian cancer is the leading cause of death among patients with gynecological malignancies worldwide, and approximately 225,000 ovarian cancers are newly diagnosed each year. The lack of an effective screening test and unfavorable anatomy are associated with advanced-stage disease at diagnosis and poor prognosis for the majority of patients. Overall survival is poor among gynecologic cancers, with a 5-year survival rate of 44% for all stages and 140,000 related deaths occurring annually worldwide, the majority of which are from high-grade serous carcinomas (HGSCs) \[[@b1-crt-2019-207]-[@b3-crt-2019-207]\].

Current estimates indicate that 20%-25% of women have an inherited germline mutation predisposing them to ovarian cancer \[[@b2-crt-2019-207]\]. In approximately 65%-85% of hereditary ovarian cancers, the associated genetic abnormality is a germline mutation of one of the *BRCA* genes (*BRCA1* or *BRCA2*). Several other tumor suppressor genes and oncogenes are also associated with hereditary ovarian cancer, including homologous recombination (HR) DNA repair genes. The Cancer Genome Atlas (TCGA) reported HR deficiency in approximately 50% of patients with high-grade serous ovarian cancer \[[@b4-crt-2019-207]\]; however, in TCGA study, the majority of patients were European, with the percentage of Asian patients being only 3.2% (19/316).

The identification of a mutation in an ovarian cancer susceptibility gene represents a fundamental step in the diagnosis and treatment of these tumors. Moreover, the identification of a mutation in patients who have already been diagnosed can provide information about the pathogenesis of their tumors. With the development of targeted therapy, current strategies for the control and prevention of ovarian cancer rely on a thorough understanding of contributing genetic factors, at both the germline and somatic levels. In this context, next-generation sequencing technologies provide an unprecedented opportunity to simultaneously analyze multiple cancer susceptibility genes, reduce delays and costs, and optimize the molecular diagnosis of hereditary ovarian cancer.

Poly(ADP-ribose) polymerase (PARP) inhibitors have shown clinical effects in patients with ovarian cancer showing *BRCA* dysfunction or homologous recombination deficiency (HRD). PARP inhibitors were originally designed for synthetic lethal interaction with *BRCA1* or *BRCA2*mutations \[[@b5-crt-2019-207],[@b6-crt-2019-207]\]. *In vitro* studies have demonstrated that defects in the other HR proteins, such as *ATM*, *CHEK1*, *CHEK2*, *NBN*, and *RAD51D*, also confer sensitivity to PARP inhibitors \[[@b7-crt-2019-207],[@b8-crt-2019-207]\]. Further, PARP inhibitors are active in a subset of sporadic (BRCA wild-type) recurrent platinum-sensitive ovarian carcinomas \[[@b9-crt-2019-207]\], which may be attributable to the influence of undetected HR gene alterations in that study. The possible application of PARP inhibitors as a therapeutic option for patients with ovarian cancer, and alterations in genes other than the *BRCA* genes, is currently under investigation (NCT-02476968, ORZORA study).

*TP53* mutation is found in many cancer types and is related to DNA damage response and apoptosis \[[@b10-crt-2019-207]\]. It is well known that *TP53* mutations are associated with poor prognosis in several cancers including ovarian cancers \[[@b10-crt-2019-207],[@b11-crt-2019-207]\]. However, the relationship between DNA damage repair (DDR) gene and *TP53* gene alterations and their combined effect on HGSC patient outcome has not been well described.

In this study, we investigated variants in DDR genes and *TP53* gene in Korean patients with HGSC, analyzed their frequency and characteristics in relation to germline and somatic *BRCA* mutations in this group, and analyzed their impact on clinical outcome to provide better prediction for PARP inhibitor therapy response.

Materials and Methods
=====================

1. Patients and specimens
-------------------------

Eligibility criteria were as follows: women aged 20 years or older with pathological diagnosis of epithelial ovarian, fallopian tube, or peritoneal carcinoma, with a high-grade serous histologic component. Patients were treated using standard treatments (cyto-reductive surgery and/or platinum-based chemotherapy) at the time of diagnosis.

Family history of cancer was recorded and confirmed by direct contact with the patients and their families. A patient was considered to have a family history of cancer if any of the following criteria were met: (1) if there were one or more cases of ovarian, peritoneal, fallopian tube, breast, pancreas, or prostate cancer among first- or second-degree relatives; or (2) if the patient had a history of primary breast cancer.

Fresh frozen or formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from the 77 patients with HGSC were analyzed. Among these 77 patients, blood samples were available from 47 patients for *BRCA* germline variant analysis. Fifty-nine cases with fresh tumor tissue, 48 available matched normal (pair in the same case) FFPE tissue for whole exome sequencing (diagnosed between the year 2005 and 2014), and 18 cases of FFPE tumor tissue for panel sequencing (diagnosed between 2017 and 2018) were obtained from the archive of Department of Pathology, CHA Bundang Medical Center. Two pathologists (H.K. and S.K.) reviewed the histology ([Fig. 1](#f1-crt-2019-207){ref-type="fig"}) using the 2014 World Health Organization classification criteria \[[@b1-crt-2019-207]\].

2. DNA sequencing and bioinformatics analysis of pathogenic variants
--------------------------------------------------------------------

Genomic DNA was extracted from a single surgical sample, containing a HGSC component, from each patient. Two different targeted sequencing assays were carried out: (1) whole exome sequencing and (2) targeted gene panel sequencing.

Fifty-nine fresh tumor samples for whole exome sequencing were snap frozen, and genomic DNA was extracted using GeneAll Exgene Clinic SV Kit columns (GeneAll, Cambio, UK), according to the manufacturer's protocols. Exomes were captured using the Agilent SureSelect Exome V5 probe set, and the captured DNA was sequ-enced on the Illumina HiSeq 2500 platform (Illumina, San Diego, CA). Sequences were aligned using BWA-0.7.15, based on Genome Reference Consortium build 37 (GRCh37). Duplicated reads were removed using Picard-tools 2.7.1, and variants were called, according to GATK 3.8 best practices (<https://software.broadinstitute.org/gatk/best-practices/>). Among the 59 patients, we performed whole exome sequencing with the matched normal FFPE lymph node tissue of 48 patients for whom the matched normal tissue was available.

For 18 FFPE tumor tissue samples for panel sequencing, genomic DNA was extracted using the RecoverAll multisample RNA/DNA isolation workflow (Invitrogen, Carlsbad, CA), according to the manufacturer's protocols. One hundred forty-three genes were targeted using the Ion Torrent Oncomine Comprehensive Assay v1 (OCA1, Thermo Fisher Scientific, Waltham, MA) and sequenced using an Ion S5 XL. Sequences were aligned using Torrent Suite 5.10.0, based on GRCh37, and variants were called with Torrent Variant Caller 5.10-9.

Thirty-eight DDR genes (including *BRCA1*/2, HR genes, mismatch repair genes) and *TP53* gene were selected for analysis of the pathogenic alterations with fresh or FFPE tissues in 77 patients.

Among them, for comparison of germline and somatic *BRCA1* and *BRCA2* variants of 29 whole exome sequencing patients and 18 panel sequencing patients were analyzed. Germline Sanger sequencing was separately conducted with blood samples in 47 patients among 77 patients ([Tables 1](#t1-crt-2019-207){ref-type="table"} and [2](#t2-crt-2019-207){ref-type="table"}).

For identifying pathogenic variants from germline common variants and reducing false-positive variants without available matched normal samples, we took three strategies of filtering out common germline or false-positive variants. Firstly, we removed variants with low qualities (QUAL score \< 30 or depth \< 20 or FILTER=FAIL). Secondly, we removed common variants (allele frequency \> 0.01) in dbSNP database (00-common_all.vcf file was downloaded on June 7, 2018) or in ExAC database (ExAC.r1.sites.vep.vcf file was downloaded on July 16, 2018). Lastly, we removed common variants in Korean (allele frequency \> 0.01) based on KOVA (K1055E_allele_frequency.txt was downloaded on November 15, 2017) and KRGDB (variants1100_cmm.txt file was downloaded on December 1, 2016 from <http://coda.nih.go.kr/coda/KRGDB>).

Fresh tumor somatic variant calls and the matched normal germline variant calls for 48 whole exome sequencing patients were carried out using the same GATK 3.8 best practice pipeline and GATK4.1-Mutect2 Tumor-Normal pair pipeline (FILTER=PASS and Depth ≥ 20), respectively. The information of germline or somatic variants is provided in [S1](#SD1-crt-2019-207){ref-type="supplementary-material"} and [S2 Tables](#SD2-crt-2019-207){ref-type="supplementary-material"}.

3. Annotation and classification of pathogenic mutations
--------------------------------------------------------

For functional annotation of each variant, ANNOVAR \[[@b12-crt-2019-207]\], Variant Effect Predictor \[[@b13-crt-2019-207]\], and Ion Reporter ver. 5.2 software (Thermo Fisher Scientific) were used. For interpretation of the pathogenicity of each variant, the three knowledge database were used; ClinVar, Oncomine Knowledge-base, and guidelines for the interpretation of sequence variants in cancer (American College of Medical Genetics) referred to Richards et al.'s study \[[@b14-crt-2019-207]\]. Among the whole exome sequencing and panel sequencing test results, information on 38 DDR genes and *TP53* gene was obtained ([S1](#SD1-crt-2019-207){ref-type="supplementary-material"}-[S3 Tables](#SD3-crt-2019-207){ref-type="supplementary-material"}). These 39 genes were selected for inclusion for a more focused analysis on *BRCA* and HRD genes. To assess the clinical impact of these genes, two subgroups according to the mutation status of *TP53* and the other 38 DDR genes of patients were separately analyzed for their survival. The groups were defined as follows: group 1 includes patients with pathogenic mutation in any of the 38 DDR genes, regardless of *TP53* mutation (n=31), and group 2 includes patients with *TP53* mutation only (n=37).

4. *BRCA* germline variant analysis
-----------------------------------

Of the 77 patients who underwent somatic genetic analysis, 47 had previously undergone germline *BRCA* testing, and genetic information on germline *BRCA* status was obtained and compared with the somatic *BRCA* test results. All germline tests were carried out using the Sanger sequencing method, as previously described \[[@b15-crt-2019-207]\].

5. Statistical analysis
-----------------------

To evaluate the differences in overall survival and diseasefree survival of the group 1 (any DDR gene mutation--positive regardless of *TP53* mutation status) and group 2 (*TP53* mutation only) were statistically significant, the log-rank test was used. Survival analysis was conducted using the survival and survminer R packages and the p-value of each Kaplan Meier-plot was calculated by log-rank test. Survival plots were depicted in ggplot2 R package.

6. Ethical statement
--------------------

Women who met the criteria (n=77) provided written informed consent between 2009 and 2018, and the study was conducted with approval from the Institutional Review Board of the CHA Bundang Medical Center (IRB approval No. 2016-10-010-005). Use of patient-derived samples for this study was approved, and the work described was performed in accordance with approved guidelines.

Results
=======

1. Patient clinical characteristics
-----------------------------------

The clinical characteristics of the 77 patients included in the study are listed in [Table 3](#t3-crt-2019-207){ref-type="table"}. The majority ethnicity was Korean, with only four individuals of Korean Chinese ethnicity. Median age at diagnosis was 56 years (range, 36 to 82 years). Primary cancers were ovary (92.2%), fallopian tube (3.9%), and peritoneum (3.9%). Histologically, the majority of tumors were HGSC. One of two patients with carcinosarcoma had HGSC in the left ovary and metastatic lesions and carcinosarcoma in only the right ovary. In this patient, only the HGSC component was used for tumor genetic testing. Approximately 90% of patients had advanced-stage disease (\> stage III). Six patients (7.8%) were previously diagnosed with breast cancer; 17 (22.1%) had a family history of breast, ovarian, fallopian tube, peritoneal, pancreas, or prostate cancer in first- or second-degree relatives. Twenty-one patients (21/77, 27.3%) had positive "family history," according to the definition used in the present study.

2. Pathogenic and likely pathogenic variants in the 38 analyzed DDR genes and *TP53* gene in tissue samples
-----------------------------------------------------------------------------------------------------------

One or more mutation in the DDR genes was identified in 40.3% of patients (31 of 77). Of the 38 DDR genes and *TP53* gene, pathogenic mutations were identified in eight genes; the remaining 31 genes were wild type. Specific details of the 98 pathogenic mutations and 63 variants of unknown significance identified in these 39 genes in the 77 patients are listed in [S1](#SD1-crt-2019-207){ref-type="supplementary-material"}-[S3 Tables](#SD3-crt-2019-207){ref-type="supplementary-material"}. Observed pathogenic and likely pathogenic mutations are shown in [Fig. 2](#f2-crt-2019-207){ref-type="fig"}. *BRCA1* (28.6%), *BRCA2* (5.2%), and *TP53* (80.5%) were the most frequently altered genes. BRCA and *TP53* mutations were detected pervasively. The frequencies of the detected variants are shown in [S4 Fig](#SD4-crt-2019-207){ref-type="supplementary-material"}. Among *BRCA* gene mutations, *BRCA1* Y130Ter variants were observed in three patients (13.6%, 3/22). The *TP53* alterations observed with frequency of more than two patients are as follows. *TP53* R175H (5.6%) and *TP53* R248Q/W (7.9%) were observed in three (4.8%) and two (3.2%) patients among 62 patients, respectively. *TP53* K132R, I195T, Y220C, and R306\* variants were observed in three patients (4.8%). *TP53* mutations were significantly enriched in DNA-binding domain (binomial test p-value=1.38e-4). The details of the *TP53* gene mutation in this study is shown in graphic chart in [S5 Fig](#SD5-crt-2019-207){ref-type="supplementary-material"}.

DDR gene alterations other than *BRCA1/2* genes were detected in (in order of frequency) *RAD50* (5.1%), *ATR* (3.4%), *MSH2* (2.6%), *FANCA* (1.7%), and *MSH6* (1.7%). One patient (Pat53) carried four mutations (*TP53*, *RAD50*, *ATR*, and *MSH2*) simultaneously, while another two patients each had three different mutations.

To assess the clinical impact of these genes, two subgroups of patients were analyzed for their survival ([Fig. 3A](#f3-crt-2019-207){ref-type="fig"}), according to the mutation status of 38 DDR genes and *TP53* gene as follows: group 1 (pathogenic mutation in any of the 38 DDR genes, regardless of *TP53* mutation); group 2 (*TP53* mutation only). The overall survival of patients in these two groups did not differ significantly (p=0.12) ([Fig. 3B](#f3-crt-2019-207){ref-type="fig"}); however, disease-free survival was different (p=0.05) ([Fig. 3C](#f3-crt-2019-207){ref-type="fig"}). The disease-free survival of patients with at least one pathogenic mutation in any of the 38 DDR genes was better than that of patients with *TP53* mutations only.

Nine patients were interpreted negative for DDR genes and *TP53* gene mutation. They were not included for survival analysis because the number of patients was too small for meaningful statistical analysis.

3. Comparison between germline and somatic BRCAmutations
--------------------------------------------------------

Pathogenic variants of *BRCA* genes were detected in 20 of the 47 patients (42.6%) in total: 17 in *BRCA1* and 3 in *BRCA2*. Among these, germline variants were identified in 16 (34.0%) of the 47 patients; 14 of the variants were in *BRCA1*, with two in *BRCA2*. Of note, four patients (8.5%) had only somatic BRCA variations without germline mutation ([Table 4](#t4-crt-2019-207){ref-type="table"}).

Discussion
==========

The most common histologic type of ovarian cancer is epithelial ovarian carcinoma (EOC), which has five subtypes: high-grade serous (70%), endometrioid (10%), clear cell (10%), low-grade serous (5%), and mucinous (3%). EOC is both clinically diverse and molecularly heterogeneous, and its subtypes have distinct gene expression patterns. Ovarian HGSC is distinct from non-HGSC, differing with respect to clinical presentation, disease distribution, response to therapy, survival, and site of origin \[[@b16-crt-2019-207]\]. Pennington et al. \[[@b17-crt-2019-207]\] repor-ted that non-HGSC cases had some *BRCA* mutations and a greater proportion of mutations in other HR genes. Therefore, we focused on tumors with HGSC histology and excluded non-HGSC tumors from the present study.

The frequency of somatic *TP53* mutations in Korean patients with HGSC in the present study was lower (80.5%) than expected. High-grade serous ovarian carcinoma is characterized by ubiquitous *TP53* abnormalities, with BRCA changes in approximately 50% of cases, along with chromosomal instability. *TP53* aberration has been considered a driver event in ovarian carcinogenesis, and it is possible that *TP53* mutations are more stable over time than other mutations. *TP53* was mutated in 95.9% of HGSC samples (303 of 316) in TCGA 2011 study \[[@b4-crt-2019-207]\]; however, in the present study, the frequency of *TP53* mutation among HGSC patients was 80.5%. When we investigated the frequency of *TP53* mutations in 10 Asian patients included in TCGA 2011 study, nine (90%) of them had *TP53* mutations. There was no statistically significant association between incidence of *TP53* mutations and ethnicity (Asian vs. others \[mostly European\]) in TCGA data set (p=0.35). Regarding the quality of sequencing, OCA1 panel that we used in this study includes the whole exon regions of *TP53* as well as whole exome sequencing, and the average coverage of all targeted regions of *TP53* in two sequencing methods were 98X for whole exome sample, and 3576X for OCA1 panel sample. We provided the sequencing coverage of overall targets and of *TP53* in each patient in [S3 Table](#SD3-crt-2019-207){ref-type="supplementary-material"}. We also confirmed that there was no statistical difference of sequencing coverage between patients with *TP53* mutation versus without *TP53* mutations. It is shown in [S6 Fig](#SD6-crt-2019-207){ref-type="supplementary-material"}. There was no statistical difference of sequencing coverage between patients with *TP53* mutations versus without *TP53* mutations, even though the average coverage values in two sequencing methods are different ([S6 Fig](#SD6-crt-2019-207){ref-type="supplementary-material"}.). However, when we investigated the *TP53* variants with low quality (depth \< 20), there were *TP53* mutations in seven patients. If we included seven *TP53* mutations with low quality, the frequency of *TP53* mutations would be 89.6%, comparable to TCGA 2011 study. The information on mutations with low quality (depth \< 20) are provided in [S7 Table](#SD7-crt-2019-207){ref-type="supplementary-material"}.

We compared the disease-free survival of the subset of HGSCs with DDR gene mutation with or without *TP53* mutation (group 1) and *TP53* mutations only (group 2) to examine the effect of these alterations on disease-free survival of the HGSC patients. The disease-free survival of group 1 was better than that of group 2 ([Fig. 3C](#f3-crt-2019-207){ref-type="fig"}), which is in accordance with previous studies that *BRCA1*, *BRCA2* gene mutation and HRD are related to favorable clinical outcome \[[@b18-crt-2019-207],[@b19-crt-2019-207]\]. *TP53* mutation status and its impact on survival is different between low grade and HGSCs, but among the HGSCs, BRCA and HR genes have more impact on survival than *TP53* mutation status.

When DDR genes are affected, the cancer cells may become more sensitive to anticancer agents directed to DNA damage such as platinum-based antineoplastic therapy. Because many anticancer therapy agents are directed to DNA damage such as alkylating agents. If the DNA damage increases without repair, it may lead to cell death. Such tumors may also produce more neoantigens due to increased mutational load. It may also elicit more immune responses to tumor and these patients may also be the candidates for cancer immunotherapy \[[@b11-crt-2019-207]\].

Estimates of the contribution of germline BRCAmutations to EOC vary widely, from 5% to 20% \[[@b20-crt-2019-207]\], and patients having somatic mutations without germline mutations in *BRCA* are less frequent, accounting for 2%-8% \[[@b21-crt-2019-207]-[@b24-crt-2019-207]\]. Germline and somatic *BRCA* mutation frequencies in EOC patients, according to the published literature, are listed in [Table 5](#t5-crt-2019-207){ref-type="table"} \[[@b4-crt-2019-207],[@b23-crt-2019-207]-[@b27-crt-2019-207]\]. As for HGSC, the lowest frequency of germline and somatic *BRCA* mutations (21.8%) is recorded in TCGA 2011 data, with the highest (20/47, 42.6%) in the present study. The mean ratio of HGSC patients with only somatic *BRCA* mutations to both germline and somatic mutations in the literature is 24.8% (range, 16.1% to 33.3%). Germline *BRCA* testing is widespread in recent clinical practice; however, this approach could miss the patients with only somatic *BRCA* mutations, who could also potentially benefit from therapy with PARP inhibitors.

Although previous reports on the effectiveness of PARP inhibitors in cancers with *BRCA* and HR repair defects have mainly focused on germline alteration of these genes, such treatment may also be effective for patients with somatic aberrations. Some patients with ovarian cancer who do not carry germline *BRCA* mutations also respond to PARP inhibitors \[[@b28-crt-2019-207]\], suggesting that broader dysfunction of genes, other than the *BRCA* genes. The patients with DDR mutation other than *BRCA* mutation may also be responsive to PARP inhibitors. The high frequency of HRD in HGSC in this study suggests that screening for this phenotype should be considered to identify candidates for PARP inhibitor treatment among these patients.

In the present study, HGSC showed somewhat higher germline and/or somatic BRCAmutation frequency in Korea (20/47 cases, 42.6%), compared with the results of previous studies (21.8%-30.1%) ([Table 5](#t5-crt-2019-207){ref-type="table"}). When we reviewed our germline and somatic genetic test results, and there were no false-positive results or variants of unknown significance. In the present study, the germline *BRCA* mutation rate (16/47 cases, 34.0%) was higher than previous reports in other countries (15.8%-25.2%), but the somatic *BRCA* mutation rate (4/47 cases, 8.5%) did not show much difference with the previous reports (4.9%-8.7%). It was reported that germline *BRCA* mutation frequency of Korean epithelial ovarian cancer patients was higher than previous reports \[[@b15-crt-2019-207]\]. In another recent study of ovarian advanced HGSC in Korean patients, germline BRCAmutation was found in 39.8% (51/128 cases), which is similar to the present study \[[@b29-crt-2019-207]\]. The possible reasons for higher rate of germline BRCAmutation in this study may be due to ethnic variation. Another reasons for differences in germline *BRCA* mutation rate maybe inclusion of primary fallopian tube or primary peritoneal HGSC cases which seem to show higher rate of *BRCA* mutation rate than primary ovarian cancer, or heterogeneity of cases included in different studies. Whether the study includes only HGSC or other epithelial ovarian cancer, inclusion of fallopian tube or primary peritoneal cancer, proportion of patients with family history may influence the detection rate of germline *BRCA* mutation.

We did not perform multiplex ligation-dependent probe amplification (MLPA) test to detect large genomic rearrangements (LGRs) in this study. Prevalence of LGRs was reported to be 1.8% in Korea at recent study \[[@b30-crt-2019-207]\]. The frequency of *BRCA* mutation would have been slightly higher if the MLPA test had been performed.

The reported prevalence of germline *BRCA* mutations in patients with fallopian tube or peritoneal cancers ranges from 15.8% to 40.9% \[[@b31-crt-2019-207]\]; however, *BRCA* mutations (two germline and two somatic) were found in four of six patients (66.7%) with fallopian tube or peritoneal cancers in the present study ([Table 4](#t4-crt-2019-207){ref-type="table"}). The one remaining patient (Pat17) with fallopian tube cancer had somatic *TP53* and *FANCA* mutations ([S3 Table](#SD3-crt-2019-207){ref-type="supplementary-material"}). Although a small number of subjects with peritoneal and fallopian tube cancers were included in this study, these cancers exhibited higher frequency of *BRCA* mutation than ovarian cancers, and all of the cases had at least one alteration among the 39 genes included in this study. These data require confirmation by further study using a larger number of cases; however, it may imply that more candidates for PARP inhibitor therapy may be detected among patients with fallopian tube or peritoneal HGSC.

In conclusion, in this study we examined variants in DDR genes and *TP53* gene in patients with ovarian HGSC. To the best of our knowledge, this study is the first to analyze somatic *BRCA1, 2* and DDR gene mutations and compare with germline and somatic *BRCA* mutations in Korean patients with HGSC. Mutations of DDR genes were observed in 40.3% (31/77), including BRCAmutations, and the frequency of *TP53* mutation (80.5%) was low compared with that in previous reports. Patients carrying somatic BRCAmutations without germline mutations were identified at a frequency of 8.5%. Although further validation in a large-scale study is needed, our data strongly indicate that more candidates for PARP inhibitor treatment can be detected by examination of somatic *BRCA* gene variants and other DDR genes, alongside germline testing for *BRCA* genes.
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Ninety-eight pathogenic and likely pathogenic variants of 39 genes in 77 patients

###### 

Sixty-three variants unknown significance in 77 patients

###### 

Summary of variants in each patient

###### 

The distribution of altered codon in *BRCA1* and *TP53* gene without hotspot (A) The bar graph shows the number of pathogenic or likely pathogenic variants in each *TP53* codon. *TP53* R175H (5.6%) and *TP53* R248Q/W (7.9%) were observed in three (4.8%) and two (3.2%) cases among 62 patients, respectively. *TP53* K132R, I195T, Y220C, and R306\* variants were observed in three patients (4.8%). (B) The bar graph shows the number of pathogenic or likely pathogenic variants in each *BRCA1* codon. *BRCA1* Y130Ter variants were observed in three patients (3/22, 13.6%).

###### 

The details of the *TP53* gene mutation in this study is shown in graphic chart. *TP53* mutations were significantly enriched in DNA-binding domain.

###### 

The *TP53* sequencing coverage in the two sequencing methods of panel sequencing and exome sequencing. (A) In panel sequencing, there was no statistical difference of *TP53* sequencing coverage between patients with *TP53* mutations and without it (t-test p-value=0.58). (B) In whole exome sequencing, there was also no statistical difference between patients with *TP53* mutations and without it. (t-test p-value=0.48).

###### 

Seven *TP53* variants with low depth (\< 20) in 77 patients

![Histologic features of high-grade ovarian serous carcinoma. (A) High-grade serous carcinoma (HGSC) composed of papillary, glandular patterns with large, hyperchromatic, pleomorphic nuclei and numerous mitoses is shown (H&E staining, ×200). (B) Diffuse strong positive reaction to immunohistochemical stain for p53 in HGSC is shown (p53 immunohistochemical stain, ×200).](crt-2019-207f1){#f1-crt-2019-207}

![Pathogenic variants (n=98) in 77 ovarian cancer patients. TP53 was mutated in 80.5% of cases, the highest frequency among the 39 genes analyzed. *BRCA1* and *BRCA2* were mutated in 28.6% and 5.2% of cases, respectively. The color of each cell represents the type of variant: blue, indel; red, stop-gain; green, missense; orange, splicing; gray, NA (data not available); and white, wild type.](crt-2019-207f2){#f2-crt-2019-207}

![The prognosis of two groups of patients, classified according to pathogenic variants. (A) Two groups were defined by their status for the pathogenic variants described in [Fig. 1](#f1-crt-2019-207){ref-type="fig"}. Group 1 consisted of patients with any pathogenic mutations in the 38 DNA damage repair genes regardless of *TP53* mutation status. Group 2 consists of patients with only *TP53* mutations. Overall survival (OS) and disease-free survival (DFS) of the two groups are shown in B and C, respectively. NA, not available.](crt-2019-207f3){#f3-crt-2019-207}

###### 

Thirty-nine genes associated with hereditary ovarian cancer

  Pathway                                         Gene
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hereditary breast and ovarian cancer syndrome   *BRCA1, BRCA2*
  Homologous recombination pathway                *ATM, ATR, BARD1, BRIP1, CHEK1, CHEK2, FAAP24, FAM175A (ABRAXAS1), FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4 (FANCP), MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54B, RAD54L*
  Mismatch repair                                 *MLH1, MSH2, MSH6, PMS2, EPCAM, MLH3*
  p53                                             *TP53*

###### 

Samples and sequencing methods

  Sample                                                         Sequencing method        No. of cases
  -------------------------------------------------------------- ------------------------ --------------
  Fresh tumor tissue                                             Whole exome sequencing   59
  FFPE tumor tissue                                              Panel sequencing         18
  FFPE matched normal lymph node tissue for fresh tumor tissue   whole exome sequencing   48
  Blood                                                          Sanger sequencing        47

FFPE, formalin-fixed paraffin-embedded.

###### 

Patient clinical characteristics

  Characteristic                                                                             No. (%) (n=77)
  ------------------------------------------------------------------------------------------ ----------------
  **Ethnicity**                                                                              
   Korean                                                                                    73 (94.8)
   Korean-Chinese                                                                            4 (5.2)
  **Age, median (range, yr)**                                                                56 (36-82)
  **Cancer site**                                                                            
   Ovary                                                                                     71 (92.2)
   Fallopian tube                                                                            3 (3.9)
   Peritoneum                                                                                3 (3.9)
  **Histology**                                                                              
   High-grade serous                                                                         73 (94.8)
   Seromucinous                                                                              2 (2.6)
   Carcinosarcoma                                                                            2 (2.6)
  **Stage**                                                                                  
   I                                                                                         2 (2.6)
   II                                                                                        6 (7.8)
   III                                                                                       59 (76.6)
   IV                                                                                        10 (13.0)
  **Breast cancer history**                                                                  
   Yes                                                                                       6 (7.8)
   No                                                                                        71 (92.2)
  **Family history of BRCA-related cancer^[a)](#tfn1-crt-2019-207){ref-type="table-fn"}^**   
   Yes                                                                                       17 (22.1)
   No                                                                                        60 (77.9)
  **Residual mass (cm)**                                                                     
   \< 1                                                                                      67 (87.0)
   ≥ 1                                                                                       10 (13.0)
  **Platinum sensitivity**                                                                   
   Sensitive                                                                                 40 (64.5)
   Resistant                                                                                 16 (25.8)
   Lost to follow-up                                                                         6 (9.7)
  **Status**                                                                                 
   NED                                                                                       15 (19.5)
   AWD                                                                                       35 (45.5)
   Death                                                                                     21 (27.3)
   Lost to follow-up                                                                         6 (7.8)

NED, no evidence of disease; AWD, alive with disease.

Family history of breast, peritoneal, ovarian, fallopian tube, pancreas, or prostate cancer in second degree relatives.

###### 

Detected *BRCA1/2* mutations in 47 patients by germline and somatic genetic test

  Case    Age (yr)   Cancer   Stage   Detected in blood and/or matched normal tissue   Detected in tumor     Germline/Somatic   Family history^[a)](#tfn2-crt-2019-207){ref-type="table-fn"}^              
  ------- ---------- -------- ------- ------------------------------------------------ --------------------- ------------------ --------------------------------------------------------------- ---------- ----
  OCA07   53         Ovary    III     *BRCA1*                                          c.2048delA            *BRCA1*            c.2048delA                                                      Germline   \+
  Pat55   59         Ovary    III     *BRCA1*                                          c.2359delG            *BRCA1*            c.2359delG                                                      Germline   --
  OCA02   47         Ovary    III     *BRCA1*                                          c.928C\>T             *BRCA1*            c.928C\>T                                                       Germline   --
  Pat10   53         Ovary    III     *BRCA1*                                          c.1716dupA            *BRCA1*            c.1716dupA                                                      Germline   \+
  Pat48   64         Ovary    III     *BRCA1*                                          c.3442G\>T            *BRCA1*            c.3442G\>T                                                      Germline   \+
  Pat20   52         Ovary    III     *BRCA1*                                          c.3700_3704delGTAAA   *BRCA1*            c.3700_3704delGTAAA                                             Germline   \+
  Pat45   61         Ovary    III     *BRCA1*                                          c.922_924delAGCinsT   *BRCA1*            c.922_924delAGCinsT                                             Germline   \+
  Pat21   55         Ovary    III     *BRCA1*                                          c.4801A\>T            *BRCA1*            c.4801A\>T                                                      Germline   \+
  Pat46   47         Ovary    III     *BRCA1*                                          c.390C\>A             *BRCA1*            c.390C\>A                                                       Germline   \+
  Pat11   65         Ovary    III     *BRCA1*                                          c.390C\>A             *BRCA1*            c.390C\>A                                                       Germline   \+
  Pat05   77         Ovary    IV      *BRCA2*                                          c.3860delA            *BRCA2*            c.3860delA                                                      Germline   \+
  Pat08   55         Ovary    III     *BRCA2*                                          c.5576_5579delTTAA    *BRCA2*            c.5576_5579delTTAA                                              Germline   \+
  OCA18   57         FTC      III     *BRCA1*                                          c.3895C\>T            *BRCA1*            c.3895C\>T                                                      Germline   \+
  OCA13   43         PPC      III     *BRCA1*                                          c.3813dupT            *BRCA1*            c.3813dupT                                                      Germline   --
  Pat41   58         Ovary    III     *BRCA1*                                          c.5496_5506delinsA    *BRCA1*            c.5496_5506delinsA                                              Germline   \+
  Pat49   48         Ovary    III     *BRCA1*                                          c.390C\>A             *BRCA1*            c.390C\>A                                                       Germline   --
  Pat47   49         Ovary    III     Not detected                                                           *BRCA1*            c.4287C\>A                                                      Somatic    --
  OCA16   55         Ovary    IV      Not detected                                                           *BRCA1*            c.969_970delAA                                                  Somatic    --
  OCA19   52         FTC      III     Not detected                                                           *BRCA1*            c.1813delG                                                      Somatic    \+
  OCA14   50         PPC      III     Not detected                                                           *BRCA2*            c.547delA                                                       Somatic    \+

FTC, fallopian tubal cancer; PPC, primary peritoneal cancer.

Family history of BRCA-related cancer within second degree relatives and/or patient history of breast cancer.

###### 

Frequency of *BRCA* germline and somatic mutations in ovarian cancer reported in the literature

  Cancer site                                            Histology               Nation of publication   Germline mutation   Somatic mutation   S/(S+G) ratio                                                 G and S mutation   Study
  ------------------------------------------------------ ----------------------- ----------------------- ------------------- ------------------ ------------------------------------------------------------- ------------------ -------------------------------------------------
  Ovary                                                  Serous and non-serous   USA                     17/28 (60.7)        11/28 (39.3)       11/28 (39.3)                                                  28/28 (100)        Hennessy et al. (2010) \[[@b24-crt-2019-207]\]
  Ovary                                                  Serous and non-serous   China                   12/50 (24.0)        2/50 (4.0)         2/14 (14.3)                                                   14/50 (28.0)       Zhaoe et al. (2017) \[[@b25-crt-2019-207]\]
  Ovary                                                  HGS                     USA                     50/316 (15.8)       20/316 (6.3)       20/69^[b)](#tfn4-crt-2019-207){ref-type="table-fn"}^ (29.0)   69/316 (21.8)      TCGA (2011)
  POFT                                                   HGS                     Canada                  26/103 (25.2)       5/103 (4.9)        5/31 (16.1)                                                   31/103 (30.1)      McAlpine et al. (2012) \[[@b26-crt-2019-207]\]
  Ovary                                                  HGS                     Italy                   10/47 (21.3)        3/47 (6.4)         3/13 (23.1)                                                   13/47 (27.7)       Mafficini et al. (2016) \[[@b23-crt-2019-207]\]
  Ovary                                                  HGS                     Taiwan                  8/46 (17.4)         4/46 (8.7)         4/12 (33.3)                                                   12/46 (26.1)       Chao et al. (2016) \[[@b29-crt-2019-207]\]
  POFT                                                   HGS                     Korea                   16/47 (34.0)        4/47 (8.5)         4/20 (20.0)                                                   20/47 (42.6)       Present study (2019)
  Total^[a)](#tfn3-crt-2019-207){ref-type="table-fn"}^                                                   110/559 (19.7)      36/559 (6.4)       36/145 (24.8)                                                 145/559 (25.9)     

Value are presented as number (%). S, somatic; G, germline; HGS, high-grade serous; POFT, peritoneal/ovarian/fallopian tube cancer.

Calculated from the five studies of HGS,

TCGA-23-1026 patient has two BRCA mutations: one germline BRCA2 K3326\* and other somatic BRCA1 G318Dfs\*2.

[^1]: Min Chul Choi and Sohyun Hwang contributed equally to this work.
